Transdermal and transmucosal powdered drug delivery

Critical Reviews in Therapeutic Drug Carrier Systems

Volumn 16, Issue 4, 1999, Pages 331-384

  Burkoth, Terry L ^a,d   Bellhouse, Brian J ^a   Hewson, Graeme ^b   Longridge, David J ^c   Muddle, Andrew G ^d   Sarphie, David F ^b  

^a Powderject Technologies Inc   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c PowderJect Pharmaceuticals plc   (United Kingdom)

^d Progenica Ltd   (United Kingdom)

Author keywords

DNA; Dry powder drug injection; Intradermal; Oral transmucosal; Peptides; Pharmacokinetics; PowderJet system; Proteins; Supersonic helium

Indexed keywords

DNA; HELIUM; INSULIN; LIDOCAINE; PEPTIDE; PROSTAGLANDIN E1; PROTEIN;

ARTICLE; BIOLISTIC TRANSFORMATION; BIOTECHNOLOGY; CLINICAL TRIAL; DEVICE; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; NONHUMAN; PARTICLE SIZE; PHARMACEUTICAL ENGINEERING; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032863151     PISSN: 07434863     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevTherDrugCarrierSyst.v16.i4.10     Document Type: Article

References (46)

1. Davis, S. S., Illum, L., and Tomlinson, E., Enzymatic barriers to peptide andprotein absorption and the use of penetration enhancers to modify absorption, in Delivery Systems for Peptide Drugs, Lee, V. H. L., New York: Plenum Press, 1986,87.
2. RobinsonJ. R. and Lee, V. H., Eds., Controlled Drug Delivery, Fundamentals and Applications, New York: Marcel Dekker, 1988.
3. Kasting, G. B., Smith, R. L., and Cooper, E. R., Effect oflipid solubility and molecular size on percutaneous absorption, in Skin Pharrnacokinetics, Shroot, B. and Schaefer, H., Eds., Basle: Karger, 1987,138.
4. Ainsden, B. G. and Goosen, M. F. A., Transdermal delivery of peptide and protein drugs: An overview, AIChEJ., 41,1972,1995.
5. Guy, R. H., Current status and future prospects of transdermal drug deliver)', Pharm. Res., 13,1765,1996.
6. Smith, E. W. and Maibach, H. L, Eds., Percutaneous Penetration Enhancers, Boca Raton, FL: CRC Press, 1995.
7. Prausnitz, M. R., Reversible skin permeabilization for transdermal delivery of macromolecules, Grit. Rev. Vier., 14(4), 455,1997.
8. Sarphic, D. F.,Johnsoii, B., Cormier, M., Burkoth, T. L., and Bellhouse, B.J., Bioavailability following transdermal powdered delivery (TPD) of radiolabeled inulin to hairless guinea pigs, J. Controlled Rel, 47,61,1997.
9. Bellhouse, B.J., Sarphie, D. F., and Greenford,J. C., Needleless syringe using supersonic gas flow for particle deliver)-, European Patent 0 693 119 Bl,January 1,1997.
10. Bellhouse, B.J., Sarphie, D. F., and GreenfordJ. C., Method of delivering powder transdermally with needleless injector, U.S. Patent 5,630,796, May 20,1997.
11. Montagiia, W. and Parakkal, P. F., Tlie Structure and Function of Skin, 3rd ed., New York: Academic Press, 1974.
12. Roberts, M. S. and Walters, K. A., Eds., The relationship between skin structure and barrier function of skin, in Dermal Absorption and Toxicity Assessment, Roberts, M.S. and Walters, K. A., Eds., New York: Marcel Dekker, 1998.
13. Kligman, A. M., Skin permeability: Dermatologie aspects of transdermal delivery, Am. Heart}., 108,200,1984.
14. Wertz, P. W. and Downing, D. T., Stratum conienm: Biological and biomédical considerations, in TraiisdermalDrugDelivery: Developmental Issues and Research Initiatives, Hadgraftj. and Guy, R. H., Eds., New York: Marcel Dekker, New York, 1989.
15. Elias, P. M., Structure and function of the stratum comeum permeability bameT,DrugDeliv. A., 13,97-105,1988.
16. Prota, G., Melanins and melanogenesis, Cosrnet. Toiletries, 111, 43-51,1996.
17. Shelley, W. B. and Lcnnart,J., The Langerhans cell: Its origin, nature and function, Ada. DermatoL, 79 (Suppl.), 7,1978.
18. Teunissen, M. B. M., Dynamic nature and function of epidermal Langerhans cells in vivo and in vitro: A review, with emphasis on human Langerhans cells, Hislochem. J. 24,697, 1992.
19. Tachibana, T., The Merkel cell: Recent findings and unresolved problems, Arch. Histol. Cytol., 58,379,1995.
20. Lavker, R. M. and Sun, T., Heterogeneity in epidermal basal keratinocytes: Morphological and functional correlations, Science, 215,1239,1982.
21. Eckert,E.L., Structure, function and differentiation of the keratinocy te, Physiol. Rev., 69, 1316,1989.
22. Jimbow, K., Lee, S. K., and King, M. G., Melanin pigments and melanosomal proteins as differentiation markers unique to normal and neoplastic melanocytes, J. Invest. Dermatol., 100,2595,1993.
23. Stablein, M. J. and Meyer,J., The vascular system and blood supply, in The Structure and Function of Oral Mucosa, MayerJ., Squier, C. A. and Gerson, S.J., Eds., New York: Pergamon Press, 237,1984.
24. Nanny, D. and Squier, C. A., Blood flow in the oral mucosa of normal and atherosclerotic monkeys, J. Dent. Res., 56 (Suppl.), 465,1982.
25. Weintraub, A. M. and Ponce de Leon, M. M. P., Potential for cross-contamination from use of a needleless injector, Am.}. Infect. Control, 26(4), 442,1998.
26. Sarpbie, D. F., Gas Propulsion of Microprojectiles for the Tranformation of Biological Cells, Ph.D. dissertation, University of Oxford, 1992.
27. Sarphie, D. F., Varadi, A., Bellhouse, B. J., and Ashcroft, S. J. H., Transdermal delivery of powdered bovine insulin to diabetic and non-diabetic Wistar rats, Diabetes, 44 (Suppl. 1) 129a, 1995.
28. Sarphie, D. F., Greenford, J., Ashcroft, S. J. H., and Bellhouse, B. J., Transdermal powdered delivery (TPD): In vivo determination of particle penetration depth and therapeutic efficacy, Proceedings of Fourth Percutaneous Penetration Conference, 4B, 1996.
29. Rathbone, M. J., Ponchel, G., and Ghazali, F. A., Systemic oral mucosal drug delivery and delivery systems, in Oral Mncosal Drug Delivery, Rathbone, M.J., New York: Marcel Dekker, 1996.
30. Bell, J. I. and Bellhouse, B. J., European Patent 9426379.5, 1994 and Bellhouse, B. J, Sarphie, D. F., and Greenford,]. C., European Patent 9502879.1,1995.
31. Duckworth, G. M., Millward, H. R., Potter, C. D. O., Hewson, G., Burkoth, T. L., and Bellhouse, B. J., Oral Powderject, a novel system for administering local anaesthetics to the oral mucosa, .Br. Dent,}., 185, (10) 536,1998.
32. Bellhouse, B. J., Quinlan, N.J., and Ainsworth, R. W., Needle-less delivery of drugs in dry powder form, using shock waves and supersonic gas flow, Plenary Lecture 6,21st International Symposium on Shock Waves, Australia, 1997.
33. Thorpe,S.J., Ainsworth,R.W.,and MannerSjR.J., Time-averaged freejet measurements using Doppler global ve\oametry,ASME Symposium on Laser Anemometry and Experimental and Numerical Flow Visualization, San Diego, CA, 1996.
34. Ainsworth, R. W., Dietz, A, J., and Nunn, T. A., The use of semiconductor sensors for blade surface measurements in a model turbine stage,_7- Eng. Gas, 113,1991.
35. Kwon, S.-Y. and Burkoth, T. L., Transdermal powder injection effect on trans-epidermal water loss (TEWL) and drug delivery, Pharm. Sei. (Suppl. 1) (1), 103,1998.
36. Etzler, F. M. and Sanderson, M. S., Particle size analysis: A comparative study of various methods, Part. Part. Sys., 12,217,1995.
37. Ghadiri, M. and Zhang, Z., Impact attrition of paniculate solids, IFPRI Final Report, FRR 16-03 University
38. Draize,J. H., Dermal and eye toxicity tests in principles and procedures for evaluating the toxicity of household substances, Washington, DC: National Academy of Sciences, 1977, 31.
39. Muddle, A. G., Longridge, D. J., Sweeney, P. A., Burkoth, T. L., and Bellhouse, B. J., Transdermal delivery of testosterone to conscious rabbits using Powd erject® A supersonic powder delivery system, Proc. Int. Symp. Control. Rel. Bicact. Mat., 24,713,1997.
40. Longridge, D. J., Sweeney, P. A., Topham, S. J., Burkoth, T. L., and Bellhouse, B. J., Effects of payload per unit area on eermal Powderject, delivery of testosterone to conscious rabbits, Proc. Int. Symp. Control. Rel. Bioact. Mat., 25,595,1998.
41. Longridge, D. J., Sweeney, P. A., Burkoth, T. L., and Belihouse, B. J., Effects of particle size and cylinderpressure on dermal Powderject delivery of testosterone to conscious rabbits, Proc. Int. Symp. Control. Rel. Bioact. Mat., 25,964,1998.
42. Ilickey, P. L., Longridge, D.J., McCrossin, L. E., Bellhouse, B.J., and Ashcroft, S. J. H., Administration of insulin via dermal Powderject®: Reproducible and dose-dependent delivery to the anaesthetised rat, November 1998 AAPS Conference, San Franscisco, 1999.
43. Lakin, M. M., Montague, D. K., VanderBrug Medendorp, S., Tesar, L., and Schover, L. R., Intracavernous injection therapy: Analysis ofresults and complications, Uni, 143(6), 1138,1990.
44. Juhlin, L. and Evers, H., Review: EMLA-a new topical anaesthetic, jWt. Dermalol., 5,75, 1990.
45. Burstein, A. and Burstein,M., Injection pain; memory, expectation and experienced pain, .A Cr.J.D.,49,183,1979.
46. Hoist, A. and Evers, H., Experimental studies of new topical anaesthetics on the oral mucosa,Szm J. Dent., 9,185,1985.